QIBA Process Coordinating Committee
March 25, 2015 at 3:00 PM CT
Call Summary

Attendees:
Kevin O’Donnell, MASc (Chair)
Daniel Sullivan, MD (Vice-chair)
Michael Boss, PhD

Staff:
Edward Jackson, PhD
Nickolas Petrick, PhD

General Discussion

• The group discussed the latest version of the template for the QIBA conformance statement (dated 03 15 2015).

• 2 different types of conformance statement were suggested:
  o Products/vendor (hardware and software)
  o Humans and sites (i.e., interaction)

• Mr. O’Donnell will add new discussion topics for template review on Google Docs based on feedback received from biomarker committee members

• Profile editors encouraged to generalize conformance details to be more applicable across multiple modalities/groups.

• The issue of whether profiles should be organ-specific was discussed. Both CT Vol and DWI are facing this. In principle, the requirements and procedures of a given profile might be equally applicable to a variety of organs, but the performance targets and groundwork evidence would need to address all the organs in the claim. Ultimately, it’s probably a choice for the Profiling Committee to evaluate.

• The group began to clarify details that are appropriate for inclusion in the annex.

• We need to consider who we expect to publish QIBA Conformance Statements, and to whom are they making claims of conformance?
  o Certainly vendors will publish conformance statements about their products to inform their customers/purchasers.
  o Investigators might also publish conformance statements about their site to inform Clinical Trialists of trials they are participating in.
  o There are probably more scenarios.

• The incorporation of geography details discussed regarding imaging sites and their satellite centers (i.e., how far reaching is the conformance statement?)

Next Call: Wednesday, April 8, 2015 at 3 PM CT